Variety of delivery options including next day & free delivery.
Pharmacy, clinic and prescribers based in Greater Manchester.
Start your treatment with a quick and free online consultation.
Variety of delivery options including next day & free delivery.
Pharmacy, clinic and prescribers based in Greater Manchester.
Start your treatment with a quick and free online consultation.
Fill in a quick online consultation for our licensed pharmacists to review.
Our pharmacists will review your treatment to ensure it’s suitable.
Your treatment will be delivered to your door quickly & discreetly.
Zomig Tablets contain zolmitriptan 2.5 mg, a selective serotonin receptor agonist (triptan) used to treat migraine attacks. Zomig works by narrowing blood vessels in the brain, relieving migraine headache pain and associated symptoms such as nausea, vomiting, and sensitivity to light and sound. It is effective only during a migraine attack and does not prevent future attacks.
Zomig Tablets are suitable for adults and available as:
| Medication Name | Zomig Tablets 2.5 mg |
| Active Ingredient | Zolmitriptan 2.5 mg |
| Other Ingredients | Hypromellose, lactose anhydrous, magnesium stearate, microcrystalline cellulose, macrogol 400 and 8000, sodium starch glycollate, titanium dioxide (E171) and yellow iron oxide (E172) |
| Medication Form | Oral tablet |
| Used to Treat | Migraine attacks with or without aura |
| Available Sizes | Packs of 6, or 12 tablets |
| Who Can Use It | Adults aged 18 years and over |
| Prescription Required? | Yes – Prescription-only medicine (POM) |
| Patient Information Leaflet | Zomig Tablets – Patient Information Leaflet |
Zomig Tablets are used to relieve migraine headache and associated symptoms like nausea, vomiting, and sensitivity to light and sound. It targets the underlying vascular changes in the brain during a migraine attack.
Zomig is suitable for adults aged 18 and over.
Do not use Zomig if you:
Avoid use if not prescribed by your doctor and follow all medical advice.
Common side effects:
Uncommon:
Rare:
Page content authored by Amjad Khan, last reviewed by Dr Hussain Ahmad on 5th March 2026.
